Can Fite Biopharma Ltd Total Assets
Can Fite Biopharma Ltd total assets. Based on the latest financial reports, Can Fite Biopharma Ltd (CANF) holds total assets worth ILA9.51 Million ILA (≈ $25.51K USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Can Fite Biopharma Ltd (CANF) market capitalisation for the company's overall valuation and market capitalisation.
Total Assets of Can Fite Biopharma Ltd (2003–2025)
Total assets of Can Fite Biopharma Ltd from 2003 to 2025. This chart illustrates how Can Fite Biopharma Ltd's total assets have evolved over time, based on quarterly financial data. See CANF stock price for real-time trading data and today's change.
Can Fite Biopharma Ltd - Asset Composition Analysis
Can Fite Biopharma Ltd Total Assets Breakdown (December 2025)
Can Fite Biopharma Ltd total assets breakdown as of December 2025. Can Fite Biopharma Ltd's total assets of ILA9.51 Million consist of 99.2% current assets and 0.8% non-current assets.
| Asset Category | Amount (ILA) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ILA0.00 | 58.1% |
| Accounts Receivable | ILA74.02K | 0.8% |
| Inventory | ILA0.00 | 0.0% |
| Property, Plant & Equipment | ILA0.00 | 0.0% |
| Intangible Assets | ILA0.00 | 0.0% |
| Goodwill | ILA0.00 | 0.0% |
Asset Composition Trend (2003–2025)
This chart illustrates how Can Fite Biopharma Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore CANF net working capital ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Can Fite Biopharma Ltd's current assets represent 99.2% of total assets in 2025, an increase from 0.0% in 2003.
- Cash Position: Cash and equivalents constituted 58.1% of total assets in 2025, down from 70.7% in 2003.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2003.
- Asset Diversification: The largest asset category is accounts receivable at 0.8% of total assets.
Can Fite Biopharma Ltd Competitors by Total Assets
Key competitors of Can Fite Biopharma Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $10.03 Billion |
|
Pharmaron Beijing Co Ltd
SHE:300759
|
China | CN¥25.80 Billion |
|
PHARVARIS N.V. EO -12
F:9EN
|
Germany | €301.45 Million |
|
GH RESEARCH PLC DL-025
F:1KA
|
Germany | €372.35 Million |
|
MoonLake Immunotherapeutics
NASDAQ:MLTX
|
USA | $400.37 Million |
|
Savara Inc
NASDAQ:SVRA
|
USA | $192.14 Million |
|
INVENTIVA ADS/1 O.N.
F:6IVA
|
Germany | €249.51 Million |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253
|
China | CN¥2.23 Billion |
Can Fite Biopharma Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.46 | 4.38 | 7.41 |
| Quick Ratio | 3.46 | 4.38 | 7.41 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | ILA6.71 Million | ILA6.93 Million | ILA8.13 Million |
Can Fite Biopharma Ltd - Advanced Valuation Insights
This section examines the relationship between Can Fite Biopharma Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.25 |
| Latest Market Cap to Assets Ratio | 0.31 |
| Asset Growth Rate (YoY) | 4.3% |
| Total Assets | ILA9.52 Million |
| Market Capitalization | $2.95 Million USD |
Valuation Analysis
Below Book Valuation: The market values Can Fite Biopharma Ltd's assets below their book value (0.31x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Can Fite Biopharma Ltd's assets grew by 4.3% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Can Fite Biopharma Ltd (2003–2025)
The table below shows the annual total assets of Can Fite Biopharma Ltd from 2003 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | ILA9.52 Million ≈ $25.51K |
+4.34% |
| 2024-12-31 | ILA9.12 Million ≈ $24.45K |
-8.70% |
| 2023-12-31 | ILA9.99 Million ≈ $26.78K |
+7.61% |
| 2022-12-31 | ILA9.28 Million ≈ $24.89K |
-54.16% |
| 2021-12-31 | ILA20.25 Million ≈ $54.30K |
+112.67% |
| 2020-12-31 | ILA9.52 Million ≈ $25.53K |
+16.50% |
| 2019-12-31 | ILA8.17 Million ≈ $21.91K |
+2.79% |
| 2018-12-31 | ILA7.95 Million ≈ $21.32K |
+1.53% |
| 2017-12-31 | ILA7.83 Million ≈ $21.00K |
-22.96% |
| 2016-12-31 | ILA10.17 Million ≈ $27.26K |
-42.24% |
| 2015-12-31 | ILA17.60 Million ≈ $47.19K |
+72.78% |
| 2014-12-31 | ILA10.19 Million ≈ $27.31K |
+53.54% |
| 2013-12-31 | ILA6.63 Million ≈ $17.79K |
+305.74% |
| 2012-12-31 | ILA1.64 Million ≈ $4.38K |
-66.65% |
| 2011-12-31 | ILA4.90 Million ≈ $13.14K |
-73.56% |
| 2010-12-31 | ILA18.55 Million ≈ $49.72K |
-7.74% |
| 2009-12-31 | ILA20.10 Million ≈ $53.89K |
-8.06% |
| 2008-12-31 | ILA21.86 Million ≈ $58.61K |
-55.32% |
| 2007-12-31 | ILA48.94 Million ≈ $131.19K |
+17.18% |
| 2006-12-31 | ILA41.76 Million ≈ $111.96K |
+12.60% |
| 2005-12-31 | ILA37.09 Million ≈ $99.43K |
+2797.42% |
| 2004-12-31 | ILA1.28 Million ≈ $3.43K |
-52.78% |
| 2003-12-31 | ILA2.71 Million ≈ $7.27K |
-- |
About Can Fite Biopharma Ltd
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction in Israel. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis. It develops Namodenoson that is in Phase … Read more